These data suggest that autocrine production of CCL2 induced prostate cancer cell migration in vitro and that in the EMT, regardless of the presence or absence of the suppression of androgen/AR signaling, prostate cancer cells with higher migration potential secreted more CCL2 (Figure 3E). The gene discussed is CCL2; the disease is prostate cancer.